由人工智能驱动的预测生物标志物发现与对比学习来改善临床试验结果
Gustavo Arango-Argoty1, Damian E Bikiel1, Gerald J Sun1
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.
Cancer cell
|April 18, 2025
概括
一个新的神经网络框架,预测生物标志物建模框架 (PBMF),自动发现从临床基因组数据预测生物标志物的发现. 这种方法在免疫瘤学临床试验中确定了改善生存率的患者子组.
科学领域:
- 计算生物学和生物信息学
- 机器学习在瘤学中
- 临床试验数据分析.
背景情况:
- 现代临床试验产生了大量的每个人临床基因组数据.
- 识别预测生物标志物,不同于预后标志物,仍然是精准医学的一个重大挑战.
- 需要自动化和公正的方法来有效地分析生物标志物发现的复杂数据集.
研究的目的:
- 引入一种新的神经网络框架,即预测生物标志物建模框架 (PBMF),用于自动和系统地发现预测生物标志物.
- 追溯地将PBMF应用于临床基因组数据集,特别是来自免疫瘤学 (IO) 试验的数据集.
- 证明该框架能够识别与改善患者存活率相关的生物标志物,并为临床决策提供信息.
主要方法:
- 开发一个利用对比学习的神经网络框架,命名为预测生物标志物建模框架 (PBMF).
- 将PBMF追溯应用到现实世界的临床基因组数据集,重点是免疫瘤学 (IO) 临床试验数据.
- 通过早期临床试验数据,验证框架识别预测生物标志物的能力.
主要成果:
- 在PBMF成功地确定了预测特定免疫瘤疗法治疗的个体更长的存活时间的生物标志物.
- 该框架通过从早期数据中发现可解释的,可预测的生物标志物,从而回顾性地为第三阶段临床试验做出了贡献.
- 与原始试验队列相比,与新型预测生物标志物识别的患者的生存风险改善了15%.
结论:
- 预测生物标志物建模框架 (PBMF) 为自动预测生物标志物发现提供了一种通用,快速和强大的方法.
- 该框架为临床试验中的生物标志物策略开发提供了可操作的见解,特别是在免疫瘤学方面.
- 通过确定可能从特定疗法中受益的患者子组,PBMF促进了改善临床决策.
关键词:
在这里,我们可以看到AIAIAI.ML ML 在 ML在NSCLCLC中,我们可以看到.生物标志物 生物标志物癌症 癌症 癌症 癌症 癌症临床试验是指临床试验中的临床试验.免疫疗法 免疫疗法俄米克斯 (Omics) 是一个电子产品.预测性的生物标志物翻译医学是一种翻译医学.更多相关视频
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
8.2K
07:15Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
Published on: August 16, 2020
6.6K
相关概念视频
02:07Improving Translational Accuracy
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
02:07Improving Translational Accuracy
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...